Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 18

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 18
---
 ag...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  interruption of, or delays in receiving, supplies of our drug candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptio...  

  limitations on employee resources that would otherwise be focused on the conduct of our non-clinical studies and clinical trials, including because of sickness of employees or their families, t...  

Risks Related to Intellectual Property

Our success depends on our ability to protect our intellectual
property and our proprietary technology.

Our success is to a certain
degree also dependent on our ability to obtain and maintain patent protection or where applicable, to receive/maintain orphan drug designation/status
and resulting marketing exclusivity for our drug candidates.

We may be materially
adversely affected by our failure or inability to protect our intellectual property rights. Without the granting of these rights,
the ability to pursue damages for infringement would be limited. Similarly, any know-how that is proprietary or particular to our
technologies may be subject to risk of disclosure by employees or consultants despite having confidentiality agreements in
place.

Any future success will depend
in part on whether we can obtain and maintain patents to protect our own products and technologies; obtain licenses to the patented technologies
of third parties; and operate without infringing on the proprietary rights of third parties. Biotechnology patent matters can involve
complex legal and scientific questions, and it is impossible to predict the outcome of biotechnology and pharmaceutical patent claims.
Any of our future patent applications may not be approved, or we may not develop additional products or processes that are patentable.
Some countries in which we may sell our drug candidate or license our intellectual property may fail to protect our intellectual property
rights to the same extent as the protection that may be afforded in the United States or Australia. Some legal principles remain unresolved
and there has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the United States,
the United Kingdom, the European Union, Australia or elsewhere. In addition, the specific content of patents and patent applications that
are necessary to support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific and
factual issues. Changes in either patent laws or in interpretations of patent laws in the United States, the United Kingdom, the European
Union or elsewhere may diminish the value of our intellectual property or narrow the scope of our patent